Literature DB >> 10052962

Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.

R M Keenan1, J F Callahan, J M Samanen, W E Bondinell, R R Calvo, L Chen, C DeBrosse, D S Eggleston, R C Haltiwanger, S M Hwang, D R Jakas, T W Ku, W H Miller, K A Newlander, A Nichols, M F Parker, L S Southhall, I Uzinskas, J A Vasko-Moser, J W Venslavsky, A S Wong, W F Huffman.   

Abstract

Previously, we reported the direct design of highly potent nonpeptide 3-oxo-1,4-benzodiazepine fibrinogen receptor antagonists from a constrained, RGD-containing cyclic semipeptide. The critical features incorporated into the design of these nonpeptides were the exocyclic amide at the 8-position which overlaid the Arg carbonyl, the phenyl ring which maintained an extended Gly conformation, and the diazepine ring which mimicked the gamma-turn at Asp. In this paper, we investigate conformational preferences of the 8-substituted benzodiazepine analogues by examining structural modifications to both the exocyclic amide and the seven-membered diazepine ring and by studying the conformation of the benzodiazepine ring using molecular modeling, X-ray crystallography, and NMR. We found that the directionality of the amide at the 8-position had little effect on activity and the (E)-olefin analogue retained significant potency, indicating that the trans orientation of the amide, and not the carbonyl or NH groups, made the largest contribution to the observed activity. For the diazepine ring, with the exception of the closely analogous 3-oxo-2-benzazepine ring system described previously, all of the modifications led to a significant reduction in activity compared to the potent 3-oxo-1, 4-benzodiazepine parent ring system, implicating this particular type of ring system as a desirable structural feature for high potency. Energy minimizations of a number of the modified analogues revealed that none could adopt the same low-energy conformation as the one shared by the active (S)-isomer of the 3-oxo-1, 4-benzodiazepines and 3-oxo-2-benzazepines. The overall data suggest that the features contributing to the observed high potency in this series are the orientation of the 3-4 amide and the conformational constraint imposed by the seven-membered ring, both of which position the key acidic and basic groups in the proper spatial relationship.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052962     DOI: 10.1021/jm980166z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).

Authors:  Carl E Wagner; Peter W Jurutka; Pamela A Marshall; Thomas L Groy; Arjan van der Vaart; Joseph W Ziller; Julie K Furmick; Mark E Graeber; Erik Matro; Belinda V Miguel; Ivy T Tran; Jungeun Kwon; Jamie N Tedeschi; Shahram Moosavi; Amina Danishyar; Joshua S Philp; Reina O Khamees; Jevon N Jackson; Darci K Grupe; Syed L Badshah; Justin W Hart
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

2.  Solid-phase synthesis of tetrahydro-1,4-benzodiazepin-2-one derivatives.

Authors:  J Zhang; W P Goodloe; B Lou; H Saneii
Journal:  Mol Divers       Date:  2000       Impact factor: 2.943

3.  Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy.

Authors:  Li Liu; Xiaoxia Liu; Qian Xu; Ping Wu; Xialin Zuo; Jingjing Zhang; Houliang Deng; Zhuomin Wu; Aimin Ji
Journal:  Int J Nanomedicine       Date:  2014-07-29

4.  Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.

Authors:  Zhongya Chen; Jiaxin Deng; Yan Zhao; Tao Tao
Journal:  Int J Nanomedicine       Date:  2012-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.